Eligibility for Intravenous Recombinant Tissue-Type Plasminogen Activator Within a Population
Top Cited Papers
- 1 June 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 43 (6), 1591-1595
- https://doi.org/10.1161/strokeaha.111.645986
Abstract
Background and Purpose— The publication of the European Cooperative Acute Stroke Study (ECASS III) expanded the treatment time to thrombolysis for acute ischemic stroke from 3 to 4.5 hours from symptom onset. The impact of the expanded time window on treatment rates has not been comprehensively evaluated in a population-based study. Methods— All patients with an ischemic stroke presenting to an emergency department during calendar year 2005 in the 17 hospitals that compromise the large 1.3 million Greater Cincinnati/Northern Kentucky population were included in the analysis. Criteria for exclusion from thrombolytic therapy are analyzed retrospectively for both the standard and expanded timeframes with varying door-to-needle times. Results— During the study period, 1838 ischemic strokes presenting to an emergency department were identified. A small proportion of them arrived in the expanded time window (3.4%) compared with the standard time window (22%). Only 0.5% of those who arrived in this timeframe met eligibility criteria for thrombolysis compared with 5.9% using standard eligibility criteria in the standard timeframe. These results did not vary significantly by repeated analysis varying the door-to-needle time or the expanded time window's exclusion criteria. Conclusions— In reality, the expanded time window for thrombolysis in acute ischemic stroke benefits few patients. If we are to improve recombinant tissue-type plasminogen activator administration rates, our focus should be on improving stroke awareness, transport to facilities with ability to administer thrombolysis, and familiarity of physicians with acute stroke treatment guidelines.This publication has 29 references indexed in Scilit:
- Recombinant Tissue-Type Plasminogen Activator Use for Ischemic Stroke in the United StatesStroke, 2011
- Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic StrokeCirculation, 2011
- Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic StrokeStroke, 2009
- Temporal Trends in Public Awareness of StrokeStroke, 2009
- Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour WindowStroke, 2009
- Treatment Time-Specific Number Needed to Treat Estimates for Tissue Plasminogen Activator Therapy in Acute Stroke Based on Shifts Over the Entire Range of the Modified Rankin ScaleStroke, 2009
- Thrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic StrokeThe New England Journal of Medicine, 2008
- FAST Stroke Prevention Educational Program for Middle School StudentsJournal of Neuroscience Nursing, 2007
- Guidelines for the Early Management of Adults With Ischemic StrokeStroke, 2007
- Tissue Plasminogen Activator for Acute Ischemic StrokeThe New England Journal of Medicine, 1995